| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 09.11. | Tevogen Inc.: Tevogen Complements Capital Access with Two-Year Extension to Loan Agreement | 2 | GlobeNewswire (USA) | ||
| 04.11. | Tevogen Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 30.09. | Tevogen Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 30.09. | Tevogen Inc.: Tevogen Regains Compliance with Nasdaq Global Market Continued Listing Requirements | 166 | GlobeNewswire (Europe) | WARREN, N.J., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Tevogen Inc. ("Tevogen" or the "Company") (Nasdaq: TVGN), an integrated healthcare enterprise combining biotechnology, artificial intelligence, and... ► Artikel lesen | |
| 18.09. | XFRA G280: WIEDERAUFNAHME/RESUMPTION | 289 | Xetra Newsboard | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
| TEVOGEN Aktie jetzt für 0€ handeln | |||||
| 10.09. | Tevogen Inc. - 8-K, Current Report | 5 | SEC Filings | ||
| 26.08. | Tevogen Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 24.08. | Tevogen Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 30.07. | Tevogen Bio Holdings Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 29.07. | Tevogen Bio becomes Tevogen Inc. | 5 | Seeking Alpha | ||
| 29.07. | Tevogen Bio Holdings Inc. Becomes Tevogen Inc. | 82 | GlobeNewswire (Europe) | WARREN, N.J., July 29, 2026 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (Nasdaq: TVGN) today announced that it will operate under the name Tevogen Inc., following approval... ► Artikel lesen | |
| 14.07. | Tevogen Bio Inc: Tevogen Bio Announces 2026 Annual Meeting of Stockholders | 1 | GlobeNewswire (USA) | ||
| 10.07. | Tevogen Bio Holdings Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 09.06. | Tevogen Bio Inc: Tevogen Announces Formation of a Healthcare Services Initiative | 710 | GlobeNewswire (Europe) | William Keane Appointed Interim Head of Initiative, Evaluating Potential Management Services Organization and Contract Research Organization Acquisitions WARREN, N.J., June 09, 2026 (GLOBE NEWSWIRE)... ► Artikel lesen | |
| 28.05. | Tevogen Bio Inc: Tevogen Advances Strategic Acquisition Initiatives with Potential to Support Approximately $100 Million in Combined Annual Revenue | 781 | GlobeNewswire (Europe) | WARREN, N.J., May 28, 2026 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (Nasdaq: TVGN) today announced continued progress across its strategic acquisition initiatives intended... ► Artikel lesen | |
| 21.05. | Tevogen Bio Inc: Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of a Management Services Organization | 586 | GlobeNewswire (Europe) | WARREN, N.J., May 21, 2026 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (Nasdaq: TVGN) today announced that it has entered into a signed, non-exclusive, non-binding Letter... ► Artikel lesen | |
| 20.05. | Tevogen Bio Holdings reports Q1 results; operating loss falls 48% | 3 | Seeking Alpha | ||
| 18.05. | Tevogen Bio Inc: Letter to Shareholders from CEO Dr. Ryan Saadi | 264 | GlobeNewswire (Europe) | WARREN, N.J., May 18, 2026 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (Nasdaq: TVGN). Dear Shareholders, Since Tevogen's 2024 public listing, we have remained focused on... ► Artikel lesen | |
| 12.05. | Tevogen Bio Inc: Tevogen Announces $3 Million Private Investment at $8 Per Share, a 14% Premium from Latest Market Close | 414 | GlobeNewswire (Europe) | WARREN, N.J., May 12, 2026 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (Nasdaq: TVGN) today announced that it has entered into a securities purchase agreement for a private... ► Artikel lesen | |
| 26.03. | Tevogen Bio Inc: Tevogen Advances Strategic CRO Evaluation to Expand Clinical Research Delivery Capabilities and Drive Revenue Growth | 424 | GlobeNewswire (Europe) | Potential transaction expected to add $20M+ in revenue and support double-digit growth, further strengthening Tevogen's position in oncology, rare diseases, and medical devicesTarget CRO operates... ► Artikel lesen |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 45,300 | +0,13 % | QIAGEN N.V.: QIAGEN Shareholders Overwhelmingly Approve Jonathan M. Pratt as Managing Director | QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that shareholders overwhelmingly approved the appointment of Jonathan M. Pratt as a Managing Director and member of the QIAGEN... ► Artikel lesen | |
| AMGEN | 422,30 | -0,05 % | Amgen Announces Positive Phase 3 Results For Dazodalibep In Sjögren's Disease | Only Global Phase 3 Trial to Show Clinically Meaningful Improvements in Systemic Disease Activity and Patient-Reported Symptoms of Sjögren's Disease THOUSAND OAKS, Calif., Nov. 11, 2026 /PRNewswire/... ► Artikel lesen | |
| VALNEVA | 2,554 | -0,89 % | Valneva meldet positive Phase-2-Daten für Shigellen-Impfstoff | Valneva hat mit seinem Impfstoffkandidaten S4V2 gegen Shigellose positive Ergebnisse aus zwei klinischen Phase-2-Studien erzielt. In einer US-amerikanischen Studie mit kontrollierter Infektion gesunder... ► Artikel lesen | |
| NOVAVAX | 7,770 | +0,39 % | Novavax: Zahlen über Plan - was Anleger jetzt prüfen sollten | ||
| REGENERON PHARMACEUTICALS | 862,00 | -0,59 % | Regeneron-Aktie: Erneute Aufwärtsbewegung nach Konsolidierung | Nach den jüngsten Quartalsergebnissen erreichte Regeneron ein neues Jahreshoch, bevor eine Konsolidierung einsetzte. Die anschließende Kurserholung hat ein höheres Tief hinterlassen, während das bisherige... ► Artikel lesen | |
| PALATIN TECHNOLOGIES | 6,230 | 0,00 % | Palatin Sinks Ahead of Q1 Results | ||
| OCUGEN | 0,755 | +0,53 % | Ocugen: Zahlen schlagen Erwartungen, aber die Aktie bleibt unter Druck - Deal im Fokus | ||
| INOVIO PHARMACEUTICALS | 1,278 | -1,84 % | INOVIO Pharmaceuticals, Inc.: INOVIO Reports Third Quarter 2026 Financial Results and Recent Business Highlights | VOCERYQ (doruxapapogene ralaplasmid and lalikinogene sifuplasmid-gxfd) granted accelerated approval by U.S. Food and Drug Administration (FDA) to reduce the frequency of surgery in adults with Recurrent... ► Artikel lesen | |
| COSCIENS BIOPHARMA | 5,020 | -3,09 % | COSCIENS Biopharma Inc. Q3 Loss Widens | ||
| VIVORYON THERAPEUTICS | 0,766 | -0,52 % | Vivoryon Therapeutics N.V. Reports Q3 2026 Financial Results and Provides Business Update | Vivoryon Therapeutics N.V. Reports Q3 2026 Financial Results and Provides Business Update
Ongoing negotiations with different parties towards securing a partnership or financing for the development... ► Artikel lesen | |
| NUREXONE BIOLOGIC | 0,319 | +3,57 % | 14 Tage oder 60 Monate Lagerung: Warum Gilead, Mesoblast und NurExone regenerative Therapien unterschiedlich verfügbar machen | ||
| BIOMARIN PHARMACEUTICAL | 51,54 | -0,73 % | 50 Prozent der neuen US-Arzneien waren Orphan Drugs: Warum BioMarin, Vertex und NurExone kleine Märkte anders entwickeln | ||
| SAREPTA THERAPEUTICS | 14,540 | -0,27 % | Sarepta Therapeutics auf Guggenheim-Konferenz: Starker Cashflow finanziert breite Entwicklungspipeline | ||
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,734 | -2,25 % | XETR NEW INSTRUMENTS AVAILABLE ON XETRA - 19.10.2026 | Folgende Wertpapiere werden in den Handel an der Frankfurter Wertpapierbörse (FWB) aufgenommen.
1. US88025U1097 10X GENOMICS INC
2. NL0000852564 AALBERTS NV
3. SE0016589188 ELECTROLUX AB
4. SE0000115446... ► Artikel lesen | |
| ARROWHEAD PHARMACEUTICALS | 42,720 | -1,41 % | Arrowhead Pharmaceuticals, Inc.: Arrowhead Pharmaceuticals to Participate in Upcoming Investor Conferences | Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming investor events:2026 Jefferies Global Healthcare Conference in London November... ► Artikel lesen |